This weekend we have the ASCO-GI biomedical meeting happening with some new data coming. See our full ASCO-GI post with catalyst readouts. See below for a table full of major events you should keep an eye on that are expected in the coming weeks. Take your biotech investing to the next level with BPIQ Premium! Learn more here.
BPIQ Weekly Catalyst Watchlist Table:
Weekly Watchlist Highlights:
Cidara has an Adcom meeting on 1/24/23 for their drug Rezafungin for the treatment of candidemia and invasive candidiasis. The NDA submission for rezafungin was supported by positive clinical data from the global ReSTORE Phase 3 and STRIVE Phase 2 clinical trials. CDTX is a BPIQ Big Mover™ stock to watch so keep it on your radar.
Viking has phase 1 data for the study of VK2735 treating metabolic disorder expected early 2023. The ongoing Phase 1 trial is a randomized, double-blind, placebo-controlled, single ascending dose (SAD) and multiple ascending dose (MAD) study. The SAD portion of the study is enrolling healthy adults, while the MAD portion of the study is enrolling healthy adults with a minimum body mass index of 30 kilograms per meter squared. The primary objectives of the study include an evaluation of the safety and tolerability of single and multiple doses of VK2735 delivered subcutaneously, as well as the identification of doses suitable for further clinical development. The trial will also evaluate the pharmacokinetics of VK2735 following single and multiple doses. Exploratory pharmacodynamic assessments include evaluations of changes in body weight and liver fat content after four weeks of once-weekly administration.
Interim Clinical Update of the Phase 1b Trial results for their lead asset ATRC-101 were presented at SITC 2022. As on Nov 10th, Atreca continued enrolling patients in its ongoing Phase 1b study of ATRC-101 based on ATRC-101 target expression in archival or newly obtained biopsies. Atreca now expects to present updated monotherapy and combination data from the trial in the first quarter of 2023.
Comments